Herpes is one of the most common viral infections in the world, yet it remains widely misunderstood. Caused by the herpes ...

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...

Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.

Wuppertal, Germany, January 29, 2026 - Aicuris Anti-infective Cures AG ("Aicuris") today announced that the company will be presenting the results of pritelivir from their pivotal Phase 3 trial (PRIOH ...

February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...

SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

Herpes simplex virus (HSV) encephalitis, caused by HSV types 1 and 2, is the most common sporadic viral encephalitis worldwide, with an annual incidence of around 2·2–4·6 per million people.1 Before ...

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

A 58-year-old woman was admitted to the hospital 3 weeks after lumbar surgery because of diplopia and fever. Left leg pain and a rash had preceded the fever and diplopia. A diagnosis was made.